Clinical Scorecard: Pregnancy Risks With First Trimester GLP-1 Continuation
At a Glance
| Category | Detail |
|---|---|
| Condition | Continuation of GLP-1 receptor agonists during the first trimester of pregnancy |
| Key Mechanisms | GLP-1 receptor agonists are used for glycemic control in patients with type 2 diabetes. |
| Target Population | Pregnant women aged 16 to 55 years who received GLP-1 receptor agonist prescriptions prior to last menstrual period. |
| Care Setting | Observational study using commercial insurance claims data. |
Key Highlights
- No clear increase in nonlive birth, abnormal fetal growth, or major congenital malformations with GLP-1 continuation.
- 30% risk of nonlive birth in continuers vs. 27% in noncontinuers; adjusted risk ratio of 1.09.
- Major congenital malformations found in about 8% of infants exposed to GLP-1 vs. 7% in noncontinuation group.
- Elective termination more frequent among patients who continued treatment.
- Similar rates of spontaneous abortion between both groups.
Guideline-Based Recommendations
Diagnosis
- Monitor pregnancy outcomes in patients continuing GLP-1 receptor agonists.
Management
- Consider individual patient circumstances regarding GLP-1 continuation during pregnancy.
Monitoring & Follow-up
- Evaluate neonatal outcomes and potential risks associated with GLP-1 receptor agonist exposure.
Risks
- Potential residual confounding related to glycemic control not fully measurable in claims data.
Patient & Prescribing Data
Pregnant women aged 16 to 55 years with prior GLP-1 prescriptions.
Most patients classified as continuers received only one additional prescription after conception.
Clinical Best Practices
- Assess pregnancy intention and concerns about drug exposure in patients considering GLP-1 continuation.
- Be aware of limitations in observational study designs when interpreting results.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
